Accelerating drug development through collaboration: The Hepatitis C drug development advisory group

C. Hutchison, A. Kwong, S. Ray, K. Struble, T. Swan, V. Miller

Research output: Contribution to journalArticlepeer-review

Abstract

Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's 1 HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.

Original languageEnglish (US)
Pages (from-to)162-165
Number of pages4
JournalClinical pharmacology and therapeutics
Volume96
Issue number2
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Accelerating drug development through collaboration: The Hepatitis C drug development advisory group'. Together they form a unique fingerprint.

Cite this